Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec with Dabrafenib and Trametinib in BRAF-Mutated Melanoma
NCT03088176Phase 1Unknown
- Sponsor
- West Cancer Center & Research Institute
- Start
- Jun 2017
- Primary completion
- Nov 2020
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec in melanoma, sponsored by West Cancer Center & Research Institute. Primary endpoint: Rate of Dose Limiting Toxicities at 2 years. Status: unknown.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03088176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088176.